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Conclusions:
The proposed acute NTCP model is able to predict ≥G3 AMT after HN cancer radiotherapy and could be useful for designing altered/ hypofractionated schedules in order to reduce the incidence of AMT. Late NTCP model was able to predict late toxicity but requires further improvements to increase the predictive power. Purpose/Objective: Current models for toxicity prediction in prostate cancer radiotherapy are based on the dose-volume histograms which lack of spatial accuracy. The goal is to propose new methods able to predict late rectal bleeding following high-dose prostate cancer radiotherapy. The aim is to fully exploit the tri-dimensional planned Dose Distribution (pDD) to study the correlation with rectal toxicity. Materials and Methods: A total of 63 patients having received a dose of 80Gy in the prostate by IMRT have been included in the study. Twelve of them presented rectal bleeding (> grade 1) at two years. Only the 3D pDD within the rectum was analysed. Our work has been divided in different steps: 1. Registration Individuals' Computed Tomography (CT) from the planning and pDD were elastically registered using the demons algorithm to a single coordinate system by combining the CTs and organs delineations.
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2.Training step
The training step consisted in learning from the data two vector subspaces spanning the 3D pDD of patients with toxicity and those of patients without toxicity, repectively. The different methods used to compute this subspaces have different constraints: orthogonality for Principal Component Analysis (PCA), mutual statistical independence for Independant Component Analysis (ICA).
3.Validation
A new patient was classified by evaluating its distances to this two subspaces. We computed the euclidean distance between this patient and it orthogonal projector in the two subspaces. Eventually, this patient is classified as toxic if the distance (dt) from the subspace representing toxic patients is less than the distance from the other subspace (dnt).
Classification
A leave-one-out cross validation and statistical measures -sensitivity and specificity -were used to evaluate the classification performance. The sensitivity assesses the percentage of toxic patients who are correctly identified as having toxicity. The specificity assesses the percentage of patients who are correctly identified as not having toxicity. Results: PCA method classified with 1 sensitivity and 0.76 specificity. ICA method allowed to classify perfectly rectal bleeding. Figure 1 shows the distance represention of each patient for ICA method. Two significant clusters were identified.
Conclusions:
Our statistical approaches conjointly exploit 3D spatial patterns of dose. pDD and late rectal bleeding appear to be correlated. However, larger data base of patients will enable to use more robust classifiers. Our results will be compared with those obtained with existing models (i .e. NTCP). Purpose/Objective: To validate the hypothesis that multi-centric learning produces better models than models built on data from individual centers only.
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Materials and Methods:
We created an IT multi-centric network, which connects the databases of 5 clinical centers across 3 European countries. The network is a federated database where certain rules apply to ensure that data privacy is preserved, data never leaves the boundaries of its institution of origin, and secure traffic through firewalls is achieved. We then tested whether learning from federated data via the network gives advantage over single-center learning in the following way. A dataset 322 non-operable and non-metastatic non-small cell lung cancer patients treated with definite (chemo)radiotherapy was distributed with unequal proportions across 5 centers.A model was built for each center using only the locally available data. A distributed learning model was deployed in the IT network which has a read-only, no-copy assess to local data. The chosen model was the Support Vector Machines (SVM) classifier, solved with the Alternating Direction Method of Multipliers method, which enables learning from data stored in different locations in a distributed way. The biggest advantage of this method is that the model learnt from scattered data across centers is exactly the same as if the data was centrally available. Results: The 5 centers had the following number of lung cancer patients available in the infrastructure: 186, 52, 45, 7 and 32, respectively. The predicted variable was 2-year survival, with predictor variables gender, World Health Organization performance status, forced expiratory volume in 1 second, number of positive lymph node stations, gross tumor volume and biologically-equivalent (at 2 Gray) total dose. No survival data was censored. We used the data at center 1 as an external validation set within the network. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Models built separately on centers 2 to 5 had AUC's of 0.75, 0.68, 0.61 and 0.72 when validated on center 1. The AUC values fluctuate substantially, which reflects to a high degree the current model-learning reality and leaves open the question of how a combined-data model would perform. We can answer this question using the network: the distributed SVM model built on all data from centers 2 to 5 without any data leaving its origin had an AUC of 0.77 on center 1 (see Figure 1) .
Conclusions:
The access to federated multi-centric data enables creating more reliable and more robust models than those based on single-center data. The infrastructure has inherent external validation capabilities that are available at virtually no extra cost of time. There is therefore an enormous potential of using such kind of infrastructure for learning more accurate and reliable medical prediction models in the future. Based on the generalized linear quadratic model (LQ) and without assuming the iso-effective hypothesis, the potential applications of the method were investigated using the clinical outcome of the biochemical relapse free survival (bRFS) recently reviewed in literature. The strength and limitation of the method, regarding the fitted parameters and 95% confidence intervals, are also discussed. Results: Our best estimate of α/β is 2.96 Gy (2.41-3.53) 95% . The correspondent α valueis 0.16 Gy -1 (0.14-0.18) 95% which is compatible with a realistic number of clonogens: 6.5·10 6 (1.5·10 6 -2.1·10 7 ) 95% . The estimated cell doubling time Td is 5.1 days (4.2-7.2) 95% , very low if compared to that reported in literature. This corresponds to the dose required to offset the repopulation occurring in one day (D prolif ) of 0.51 Gy/day (0.32-0.68) 95% . However, a long kick-off time T k of 31 days (22-41) 95% from the start of radiotherapy was found. Conclusions: The proposed analytical/graphical method has allowed to fit clinical data providing a self-consistent set of radiobiological parameters for prostate cancer. With our analysis we confirm a low value for α/β with a correspondingly high value of intrinsic radiosensitivity, a realistic average number of clonogens, a long kickoff time for accelerated repopulation and a surprisingly fast repopulation that suggests the involvement of subpopulations of specifically tumorigenic stem cells during the continuing radiotherapy. Purpose/Objective: Standardized Total Average Toxicity (STAT) score was proposed by Barnett (IJROBP11) as a global score which may be used to: (a) facilitate the analysis of overall radiation (RT) toxicity (tox) (b) pool data from multiple trials (in order to increase statistical power) (c) select patients (pts) to be included in studies of possible genetic determinants of RT tox. In the same paper application of STAT to 2 cohorts of breast cancer pts was presented. We here evaluate application of STAT to 2 prostate cancer populations (A and B) , with the aim of verifying that STAT keeps all known correlations of single tox endpoints with clinical/dosimetric risk factors and to select possible radiosensitive pts Materials and Methods: Population A (646 pts, doses 70-80Gy,1.8-2Gy/fr) was included in a prospective trial on rectal tox (recorded by questionnaires). Population B (179 pts, doses 60-80Gy,1.8-2.65Gy/fr) was included in a prospective trial on genito-urinary tox (measured by IPSS). STAT calculation was made following definition by Barnett. Key point is that STAT defines whether a pt's global tox is high or low relative to the distribution of the global tox of other pts. STAT measures the distance between the single pt and the average of all considered pts in terms of standard deviations. For population A, 2 STATs were considered: baseline STAT (BSTAT) and late (3yrs follow-up) STAT (STATGI). For population B, only acute tox was available and acute STAT (STATGU) was calculated. We considered pts with STATGI/STATGU>0.8 as exhibiting high tox with respect to the whole cohort and clinical/dosimetric predictors of STATGI/STATGU>0.8 were determined through multivariable logistic analysis. Analysis of residuals was used to individuate the radiosensitive cohorts Results: STATGI>0.8 (43/646pts) was predicted by: BSTAT (continuous variable (cv), OR=2, p=0.04), previous diseases of the colon (OR=3, p=0.02), the % volume of rectum receiving more than 40Gy (V40Gy, cv, OR=1.02, p=0.08) and V75Gy (cv, OR=1.05, p=0.03). Overall p=0.0006, AUC 0.74. STATGU>0.8 (39/179pts) was predictedby: pre-RT IPSS (cv, OR=1.14, p=0.0008), Body Max Index (cv, OR=0.94, p=0.2), clinical T3 stage (OR=2, p=0.1), absolute bladder surface receiving ≥8.5 Gy/week (cv, OR=1.014, p=0.03) and absolute bladder surface receiving ≥12.5 Gy/week (cv, OR=1.035, p=0.06). Overall p<0.0001, AUC 0.81. From analysis of residuals, 14 and 11 pts emerged as possible radiosensitive pts (with high STAT which is not predicted from model) for STATGI and STATGU, respectively.
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Conclusions:
Correlation between high STATGI/STATGU and clinical/dosimetric risk factors confirmed previously results found in the 2 populations for the single tox endpoints. This global approach allows objective identification of pts whose tox are not explained by the global model and who may be included in studies of possible genetic determinants of RT tox
